• In recent days, Bunge Global has come under pressure after reporting negative free cash flow and declining earnings per share, despite maintaining relatively steady sales growth and an unfavorable liquidity profile. Investors are increasingly focused on the possibility that ongoing weak cash generation could force the company to pursue equity financing that would dilute existing shareholders.
• We will now explore how these concerns about negative free cash flow and potential dilution could reshape Bunge Global's previously optimistic investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Bunge Global Investment Narrative Recap

To own Bunge Global, you need to believe its integrated agribusiness platform and Viterra combination can turn strong sales into healthier, more reliable cash generation. The latest reports of negative free cash flow and falling EPS raise the stakes on that belief, because persistent weak cash could make dilution a more immediate risk than previously thought, even as long term demand for grains, oils and biofuels remains the core upside catalyst.

Against this backdrop, Bunge’s recent Q1 2026 results stand out: sales rose to US$21,861 million, yet net income dropped to US$68 million and EPS slid to US$0.35. That widening gap between revenue and earnings is central to today’s concerns about cash flow, liquidity and potential equity issuance, and it could influence how investors view the timing and payoff of the Viterra integration and ongoing capital projects.

Yet the bigger concern investors should be aware of is how sustained negative free cash flow could eventually...

Bunge Global's narrative projects $100.1 billion revenue and $3.8 billion earnings by 2029. This requires 7.5% yearly revenue growth and about a $3.1 billion earnings increase from $686.0 million today.

Uncover how Bunge Global's forecasts yield a $142.00 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting earnings to reach about US$2.9 billion, but with free cash flow now negative, those upbeat assumptions on margins and cash generation may face a serious test.

Explore 3 other fair value estimates on Bunge Global - why the stock might be worth over 6x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bunge Global research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Bunge Global research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bunge Global's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.